trial · primary record
Mirdametinib
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2033-01-01 |
| Primary endpoint | Phase 1: determine the RP2D of the mirdametinib in combination with sirolimus in participants with RAS-mutated RRMM |
| Registry ID | NCT06876142 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:17.938Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06876142
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.